Anixa Biosciences Inc

Anixa Biosciences Inc. filed its 10-Q report for the period ending April 30, 2026. The company reported a net loss of $5.121 million for the six months ended April 30, 2026, a decrease from $6.026 million in the same period last year. Total assets and shareholders' equity saw a decrease, while liabilities also reduced. The company raised approximately $2.870 million through an at-the-market equity offering and continued to invest in research and development, with R&D expenses totaling $2.360 million for the six-month period.